Can Affymetrix (AFFX) Surprise This Earnings Season? - Analyst Blog

Loading...
Loading...

We expect healthcare services provider Affymetrix Inc. AFFX to beat expectations when it reports first-quarter fiscal 2014 operating results on May 1, 2014, after the market closes.

Why a Likely Positive Surprise?

Our proven model shows that Affymetrix is likely to beat earnings because it has the right combination of two key ingredients.

Zacks ESP: Expected Surprise Prediction or Earnings ESP represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate. Affymetrix has a Zacks ESP of +50.00%. This is very meaningful and a leading indicator of a likely positive earnings surprise for shares.

Zacks Rank: Affymetrix carries a Zacks Rank #2 (Buy). Note that stocks with Zacks Ranks #1, 2 and 3 have a significantly higher chance of beating earnings. The Sell-rated stocks (#4 and 5) should never be considered going into an earnings announcement.  

The combination of Affymetrix's Zacks Rank #2 (Buy) and +50.00% ESP makes us confident of a possible positive earnings beat on May 1. It is worth noting that Affymetrix had delivered positive earnings surprises in 2 of its last 4 quarters, with an impressive average beat of 192.86%.

What is Driving the Better-than-Expected Earnings?

In its last reported fourth-quarter 2013, Affymetrix had reported adjusted earnings of 2 cents per share, rebounding from an adjusted loss of 2 cents per share incurred in the same quarter a year ago. However, earnings lagged the Zacks Consensus Estimate by 71.43%.

Moreover, Affymetrix experienced solid year-over-year growth of 9.8% in revenues to $92.6 million. This hike in total revenues can be attributable to increased CytoScan and Axiom revenues in the company's Genetic Analysis business units.

Fourth-quarter adjusted operating expenses dropped 1.2% year over year to $47.9 million, primarily driven by lower headcount following the restructuring announced on Jan 11, 2013.

Based on its encouraging performance in the past quarter, Affymetrix expects to generate revenues of approximately $335 million in 2014. The company also expects EBITDA to hover in the range of 12-13% in 2014.

Other Stocks to Consider

Affymetrix is not the only firm looking up this earnings season. We also see likely earnings beats coming from these 3 industry peers:

Myriad Genetics Inc. MYGN, earnings ESP of +10.87% and a Zacks Rank #1 (Strong Buy).

Alexion Pharmaceuticals, Inc. ALXN, earnings ESP of +5.56% and a Zacks Rank #1 (Strong Buy).

Gilead Sciences Inc. GILD, earnings ESP of +17.32% and a Zacks Rank #1 (Strong Buy).



AFFYMETRIX INC AFFX: Free Stock Analysis Report

ALEXION PHARMA ALXN: Free Stock Analysis Report

GILEAD SCIENCES GILD: Free Stock Analysis Report

MYRIAD GENETICS MYGN: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Loading...
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...